Gene Therapy for Blindness Using Light-Sensitive Ion Channels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating blindness, particularly retinal blindness, are inadequate due to insufficient electrode numbers in retinal prostheses and issues with foreign body insertion, as well as challenges in making cells light-sensitive using existing genetic and non-genetic approaches.
Innovation Solution
Expression of depolarizing light-sensitive molecules in retinal photoreceptors using specific nucleic acid molecules and promoters, such as channelrhodopsin-2, to restore vision by making cells photosensitive, even in disease states where normal polarization is inverted.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If retinal prosthesis with electrodes is used to treat blindness, then vision restoration is achieved, but the number of electrodes is insufficient to provide high degree of sight and foreign body insertion problems arise
Solution Approach 1:
The patent replaces the mechanical electrode-based retinal prosthesis system with a genetic approach using light-sensitive proteins (opsins) and ion channels. Instead of implanting foreign bodies with electrodes, the invention uses viral vectors to deliver genes that encode light-sensitive molecules, which are then expressed in retinal cells to restore photosensitivity naturally without mechanical components
Solution Approach 2:
The patent introduces viral vectors as intermediaries to deliver the genetic material encoding light-sensitive proteins into retinal cells. The viral vectors serve as mediators between the external delivery system and the target retinal cells, enabling efficient gene transfer and expression without direct mechanical intervention in the retina
2Reliability
If microbial-type rhodopsin is expressed to restore visual responses, then light sensitivity is restored, but the threshold light intensity required is much higher than for normal photoreceptors
Solution Approach 1:
The patent modifies the properties of light-sensitive proteins by using engineered ion channels with specific conductance properties and by optimizing the expression levels of opsin proteins. The invention changes parameters such as ion channel conductance, protein expression levels, and channel density in retinal cells to lower the threshold light intensity required for activation, making the system responsive to physiological light levels
Solution Approach 2:
The patent creates a composite system combining multiple light-sensitive components including opsin proteins, ion channels, and supporting cellular structures. This composite approach integrates different functional elements (light absorption by opsins, ion conduction through channels, signal amplification through cellular mechanisms) to achieve sensitive visual responses at physiological light intensities
3Reliability
If channelrhodopsin-2 is targeted to ON-cells to restore vision, then vision restoration is achieved, but the approach is sub-optimal for OFF-cells
Solution Approach 1:
The patent develops a universal genetic approach using cell-type-specific promoters that can drive expression of appropriate light-sensitive proteins in different retinal cell types (ON-cells, OFF-cells, bipolar cells, ganglion cells). The system is designed to be adaptable to multiple cell types by changing the promoter element, allowing the same basic mechanism to restore vision across diverse retinal neurons with different functional properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively tunes retinal responses and enables vision restoration by making retinal cells responsive to light, potentially improving vision in conditions like macular degeneration and retinitis pigmentosa, even in early stages of retinal degeneration.
Implementation Method 1
channelrhodopsin-2, a light-gated ion channel from the alga Chlamydomonas reinhardtii
Implementation Method 2
expression of depolarizing light-sensitive molecules in retinal photoreceptors using specific nucleic acid molecules and promoters, such as channelrhodopsin-2
Data Source
AI summary
The present inventions relates to an isolated nucleic acid molecule comprising a nucleotide sequence coding for a depolarizing light-gated ion channel functionally linked to a promoter leading to the specific expression of said depolarizing light-gated ion channel in a retinal photoreceptor, or the nucleotide sequence complementary to said nucleotide sequence, for use in treating or ameliorating blindness. The present invention also relates to methods of using such nucleic acid molecules in the treatment of blindness.